

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/020409-2022>

Planning

PCR Molecular Testing

University Hospitals Birmingham NHS Foundation Trust

F01: Prior information notice

Prior information only

Notice identifier: 2022/S 000-020409

Procurement identifier (OCID): ocids-h6vhtk-03565e

Published 27 July 2022, 9:19am

Section I: Contracting authority

I.1) Name and addresses

University Hospitals Birmingham NHS Foundation Trust

14-17 George Road

Birmingham

B15 1NU

Contact

Leanne Wingrove

Email

leanne.wingrove@uhb.nhs.uk

Telephone

+44 1213712000

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

www.uhb.nhs.uk

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

Additional information can be obtained from the above-mentioned address

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

PCR Molecular Testing

II.1.2) Main CPV code

- 85111800 - Pathology services

II.1.3) Type of contract

Services

II.1.4) Short description

University Hospitals Birmingham NHS Trust are looking at tendering for PCR Molecular Testing Platforms in order to carry out rapid molecular testing.

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 85111800 - Pathology services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The Molecular Pathology Diagnostic Service (MPDS) at UHB needs to be able to deliver a quick and highly sensitive assessment of RET and MET alterations in lung cancer samples, which is required prior to the prescription of drugs targeting RET and MET.

A quick turn around time is required, since lung cancer patients need to be started on the treatment as soon as possible.

Lung tumour samples are of small size; there is therefore a need for a highly sensitive technology with a very low rate of failure.

MPDS receives at least 350 lung cancer samples every month for MET exon 14 mutation and RET translocation testing; the numbers are likely to increase; the technology therefore needs to be adaptable to the needs.

In order to take into account the various clinical circumstances, the technology needs to allow MPDS to perform RET and MET exon 14 alterations within a few hours for selected tumours.

II.3) Estimated date of publication of contract notice

1 November 2022

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section VI. Complementary information

VI.3) Additional information

Due to Issues with the portal the PIN has been republished for an additional week.